Concord Biotech Ltd
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]
- Market Cap ₹ 15,375 Cr.
- Current Price ₹ 1,470
- High / Low ₹ 2,452 / 1,345
- Stock P/E 43.2
- Book Value ₹ 173
- Dividend Yield 0.73 %
- ROCE 28.2 %
- ROE 21.3 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 18.6% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 28.0%
Cons
- Stock is trading at 8.48 times its book value
- Company has high debtors of 159 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 512 | 616 | 713 | 853 | 1,017 | 1,200 | 1,188 | |
| 308 | 289 | 443 | 509 | 585 | 694 | 706 | |
| Operating Profit | 205 | 327 | 270 | 344 | 432 | 506 | 482 |
| OPM % | 40% | 53% | 38% | 40% | 42% | 42% | 41% |
| 32 | 14 | 23 | 37 | 37 | 44 | 51 | |
| Interest | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation | 21 | 28 | 50 | 54 | 54 | 54 | 59 |
| Profit before tax | 214 | 313 | 238 | 322 | 413 | 495 | 474 |
| Tax % | 21% | 25% | 26% | 25% | 25% | 25% | |
| 169 | 235 | 175 | 240 | 308 | 372 | 356 | |
| EPS in Rs | 177.81 | 247.44 | 183.93 | 22.95 | 29.45 | 35.52 | 34.04 |
| Dividend Payout % | 22% | 0% | 3% | 30% | 30% | 25% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 19% |
| TTM: | 14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 28% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -19% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 21% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 761 | 990 | 1,094 | 1,280 | 1,516 | 1,802 |
| 52 | 86 | 62 | 32 | 10 | 3 | |
| 118 | 97 | 147 | 192 | 164 | 219 | |
| Total Liabilities | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 |
| 240 | 546 | 573 | 593 | 575 | 795 | |
| CWIP | 141 | 18 | 74 | 173 | 211 | 51 |
| Investments | 199 | 141 | 74 | 137 | 246 | 335 |
| 361 | 477 | 592 | 611 | 668 | 854 | |
| Total Assets | 941 | 1,183 | 1,313 | 1,514 | 1,701 | 2,034 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 155 | 167 | 207 | 246 | 265 | 245 | |
| -114 | -195 | -112 | -158 | -155 | -160 | |
| -43 | 31 | -100 | -85 | -99 | -99 | |
| Net Cash Flow | -1 | 3 | -4 | 3 | 12 | -14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 131 | 105 | 119 | 117 | 125 | 159 |
| Inventory Days | 312 | 503 | 434 | 430 | 331 | 286 |
| Days Payable | 201 | 152 | 185 | 190 | 150 | 135 |
| Cash Conversion Cycle | 242 | 456 | 368 | 357 | 306 | 310 |
| Working Capital Days | 159 | 177 | 161 | 152 | 166 | 193 |
| ROCE % | 32% | 21% | 26% | 28% | 28% |
Documents
Announcements
-
Successful Completion Of NAFDAC Inspection
8 Oct - NAFDAC inspection at Valthera OSD Unit-2 completed Oct 6–7, 2025; compliance affirmed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
6 Oct - Certificate under Reg 74(5) confirming dematerialisation actions for quarter ended Sep 30, 2025.
-
Closure of Trading Window
25 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited results for quarter ended 30 Sep 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep - Of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR), Regulations 2015 on 19th September, 2025 at 11:00 AM IST
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Sep - Analyst/institutional investor meetings on 17 Sep 2025 with Jefferies India in New Delhi; discussions on public information.
Concalls
-
Aug 2025Transcript PPT
-
Jun 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Sep 2023TranscriptPPT
-
Sep 2023Transcript PPT
Business Profile[1]
Concord Biotech is a pharmaceutical company headquartered in Ahmedabad, Gujarat, specializing in Active Pharmaceutical Ingredients (APIs) and formulations. The company is engaged in development and manufacturing of niche fermentation-based APIs and finished dosage formulations for domestic and international markets.